We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the ...

Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

Regeneron invested $119.5 million in Truveta ... than 10 times the scale of other health care databases, such as the UK Biobank, which includes 500,000 participants recruited between 2006 ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Future of Healthcategory· February 24, 2025 Regeneron's gene therapy study shows improved hearing in children with congenital deafness Regeneron Pharmaceuticals said on Monday its experimental ...